CLINICAL TRIALS PROFILE FOR NORVIR
✉ Email this page to a colleague
All Clinical Trials for Norvir
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002447 ↗ | A Study to Compare Two Anti-HIV Drug Combinations | Completed | Hoffmann-La Roche | Phase 3 | 1999-10-01 | The purpose of this study is to compare 2 anti-HIV drug combinations. |
NCT00005017 ↗ | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment | Unknown status | Glaxo Wellcome | Phase 4 | 1969-12-31 | The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV). |
NCT00051831 ↗ | Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults | Completed | AIDS Clinical Trials Group | N/A | 2003-10-01 | HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Norvir
Condition Name
Clinical Trial Locations for Norvir
Trials by Country
Clinical Trial Progress for Norvir
Clinical Trial Phase
Clinical Trial Sponsors for Norvir
Sponsor Name